Focus remains on DFUS; valuations priced in

Company
11 Mar 2024
5 Min read 
  • Alkem is a pharmaceutical company focused on domestic formulation segment.
  •  Strong presence in acute therapies, growth dependent on seasonality and infection rates.
  •  US sales growing with reduced price erosion and market share gains.
  •  Non-US exports showing healthy growth.
  •  Enzene subsidiary focusing on biosimilars and CDMO business, aiming for breakeven in FY25.
  •  Neutral stance on stock due to high valuation and adequately factored earnings upside.
Login / Open Demat Account to read the report

Never Miss Out on Hot Market Updates

Get exclusive market news delivered to your inbox - on priority